Free Trial
NASDAQ:CPRX

Catalyst Pharmaceuticals (CPRX) Stock Price, News & Analysis

Catalyst Pharmaceuticals logo
$19.86 +0.22 (+1.12%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$19.77 -0.09 (-0.43%)
As of 08/8/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Catalyst Pharmaceuticals Stock (NASDAQ:CPRX)

Key Stats

Today's Range
$19.48
$20.08
50-Day Range
$19.64
$26.31
52-Week Range
$17.58
$26.58
Volume
2.24 million shs
Average Volume
1.39 million shs
Market Capitalization
$2.42 billion
P/E Ratio
12.04
Dividend Yield
N/A
Price Target
$33.20
Consensus Rating
Buy

Company Overview

Catalyst Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
98th Percentile Overall Score

CPRX MarketRank™: 

Catalyst Pharmaceuticals scored higher than 98% of companies evaluated by MarketBeat, and ranked 33rd out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Catalyst Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Catalyst Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Catalyst Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Catalyst Pharmaceuticals are expected to grow by 12.11% in the coming year, from $1.90 to $2.13 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Catalyst Pharmaceuticals is 12.04, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.88.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Catalyst Pharmaceuticals is 12.04, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.76.

  • Price to Earnings Growth Ratio

    Catalyst Pharmaceuticals has a PEG Ratio of 0.80. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    Catalyst Pharmaceuticals has a P/B Ratio of 2.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    7.31% of the outstanding shares of Catalyst Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Catalyst Pharmaceuticals has a short interest ratio ("days to cover") of 7.4.
  • Change versus previous month

    Short interest in Catalyst Pharmaceuticals has recently increased by 9.18%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Catalyst Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Catalyst Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.31% of the outstanding shares of Catalyst Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Catalyst Pharmaceuticals has a short interest ratio ("days to cover") of 7.4.
  • Change versus previous month

    Short interest in Catalyst Pharmaceuticals has recently increased by 9.18%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Catalyst Pharmaceuticals has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 14 news articles for Catalyst Pharmaceuticals this week, compared to 7 articles on an average week.
  • Search Interest

    23 people have searched for CPRX on MarketBeat in the last 30 days. This is an increase of 28% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added Catalyst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Catalyst Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,879,369.00 in company stock.

  • Percentage Held by Insiders

    10.40% of the stock of Catalyst Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    79.22% of the stock of Catalyst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Catalyst Pharmaceuticals' insider trading history.
Receive CPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CPRX Stock News Headlines

BREAKING: The House just passed 3 pro-crypto bills!
THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here.
See More Headlines

CPRX Stock Analysis - Frequently Asked Questions

Catalyst Pharmaceuticals' stock was trading at $20.87 at the beginning of 2025. Since then, CPRX stock has decreased by 4.8% and is now trading at $19.86.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) released its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported $0.10 EPS for the quarter, meeting the consensus estimate of $0.10. The biopharmaceutical company earned $35.95 million during the quarter, compared to analysts' expectations of $34.47 million. Catalyst Pharmaceuticals had a trailing twelve-month return on equity of 40.78% and a net margin of 37.36%.
Read the conference call transcript
.

Catalyst Pharmaceuticals' top institutional shareholders include Geode Capital Management LLC (2.35%), Boston Partners (1.05%), Allianz Asset Management GmbH (0.85%) and Bank of New York Mellon Corp (0.59%). Insiders that own company stock include Patrick J Mcenany, Steve Miller, David S Tierney, Donald A Denkhaus, Richard J Daly, Brian Elsbernd, Philip H Coelho, Gary Ingenito, Alicia Grande, Preethi Sundaram, Carmen Jeffrey Del and Molly Harper.
View institutional ownership trends
.

Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Catalyst Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), Adobe (ADBE) and ServiceNow (NOW).

Company Calendar

Last Earnings
11/09/2021
Today
8/09/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CPRX
CIK
1369568
Employees
80
Year Founded
2002

Price Target and Rating

High Price Target
$36.00
Low Price Target
$30.00
Potential Upside/Downside
+65.3%
Consensus Rating
Buy
Rating Score (0-4)
3.25
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
$1.57
Trailing P/E Ratio
12.04
Forward P/E Ratio
10.45
P/E Growth
0.8
Net Income
$163.89 million
Net Margins
37.36%
Pretax Margin
48.70%
Return on Equity
40.78%
Return on Assets
35.36%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.71
Quick Ratio
5.96

Sales & Book Value

Annual Sales
$491.73 million
Price / Sales
4.93
Cash Flow
$2.47 per share
Price / Cash Flow
8.03
Book Value
$7.02 per share
Price / Book
2.83

Miscellaneous

Outstanding Shares
121,970,000
Free Float
109,290,000
Market Cap
$2.42 billion
Optionable
Optionable
Beta
0.70

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:CPRX) was last updated on 8/9/2025 by MarketBeat.com Staff
From Our Partners